| abstract |
The present disclosure provides antibodies that specifically bind to CTLA-4 (eg, human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising the antibodies, nucleic acids encoding the antibodies, expression vectors and host cells for producing the antibodies, and methods of treating a subject using the antibodies. |